HHS budget proposal eliminates CDC's chronic disease, global health centers in favor of new "MAHA" agency

The HHS budget proposal for FY2026 seeks to consolidate 28 divisions into 15, establishing the new Administration for a Healthy America (AHA) with a $20.6 billion budget, significantly restructuring and defunding existing programs. Key changes include slashing the CDC's budget from $9.2 billion to $4.2 billion, eliminating the CDC's chronic disease and global health centers, and cutting the NIH by approximately 40%, with some funds redirected to AHA's "root cause" approach to chronic disease prevention; these proposed cuts have drawn criticism from health organizations citing potential destabilization of public health systems and jeopardizing decades of progress.

Analysis

The proposed FY2026 HHS budget outlines a significant restructuring of U.S. public health agencies, involving the consolidation of 28 divisions into 15 and the establishment of a new $20.6 billion entity, the Administration for a Healthy America (AHA). This reorganization entails substantial budgetary shifts, most notably a reduction in the Centers for Disease Control and Prevention (CDC) budget from $9.2 billion in FY2024 to $4.2 billion, with at least $1 billion of the cut funds being reallocated to AHA. Key CDC components, including its $1.4 billion Chronic Disease Prevention and Health Promotion center and its $711 million Global Health Center, are slated for elimination, with global health activities to receive a reduced $239 million under a broader CDC budget line. Concurrently, the National Institutes of Health (NIH) faces an approximate 40% budget cut, and agencies like the Substance Abuse and Mental Health Services Administration (SAMHSA) are set to be dissolved. While the administration frames these changes as a move towards a "root cause" approach to chronic disease and fiscal prudence, the proposal has elicited strong opposition from numerous health organizations. Critics highlight potential disruptions to public health systems, which heavily rely on CDC funding (state and local departments received $4.5 billion in the past year), the loss of critical human capital and expertise in areas like infectious disease surveillance, and a diminished U.S. capacity to address global health threats. The consolidation and reduction of funding for programs such as HIV/AIDS prevention, which sees a nearly $1 billion cut, further underscore the transformative and potentially contentious nature of this budgetary overhaul.

Key Decisions for Investors

• Investors should critically assess portfolios for exposure to pharmaceutical and biotechnology companies heavily reliant on National Institutes of Health (NIH) grants, as the proposed approximate 40% cut to the NIH budget presents a substantial risk to their research and development funding.
• Companies operating in the chronic disease prevention and management sector may face a shifting landscape; the elimination of the CDC's dedicated chronic disease center and redirection of funds to the new Administration for a Healthy America (AHA) warrants a re-evaluation of their alignment with new federal priorities and funding mechanisms.
• Given the proposed elimination of the CDC's Global Health Center and significant funding reductions, firms specializing in global infectious disease surveillance, pandemic preparedness, and international health aid should anticipate potential contractions in U.S. government contracts and support.
• Consider the downstream impact on healthcare service providers and suppliers to state and local health departments, as the substantial cut to the CDC's budget, a primary funding source for these entities ($4.5 billion in FY2024), could lead to reduced spending and operational challenges for these organizations.